Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium
暂无分享,去创建一个
P. Whelton | G. Stone | G. Parati | A. Finn | G. Grassi | M. Krucoff | P. Jüni | M. Böhm | R. Schmieder | R. Mehran | D. Kandzari | M. Morice | V. Papademetriou | D. Cutlip | A. Kirtane | A. Pathak | F. Mahfoud | P. Lurz | M. Azizi | J. Daemen | K. Tsioufis | M. Myers | M. Schlaich | E. Spitzer | Andrew S. P. Sharp | C. Ukena | M. Lobo | Andrew S P Sharp | N. Fisher | Michael A Weber | R. Townsend | Michael Bloch | Michael A. Weber | P. Jüni | M. Böhm | K. Tsioufis | Michael Bloch | Michael J Bloch
[1] M. Middeke,et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. , 2021, The New England journal of medicine.
[2] K. Kario,et al. Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. , 2021, Journal of the American College of Cardiology.
[3] P. Neužil,et al. Pacemaker‐Based Cardiac Neuromodulation Therapy in Patients With Hypertension: A Pilot Study , 2021, Journal of the American Heart Association.
[4] R. Townsend,et al. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF , 2021, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[5] M. Uder,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial , 2021, The Lancet.
[6] S. Pocock,et al. Changes in Plasma Renin Activity after Renal Artery Sympathetic Denervation. , 2021, Journal of the American College of Cardiology.
[7] Dave L Dixon,et al. Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. , 2021, Journal of the American College of Cardiology.
[8] G. Parati,et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. , 2021, Journal of hypertension.
[9] Sathish Kumar Jayapal,et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.
[10] S. Pocock,et al. Prioritized Endpoints for Device-Based Hypertension Trials: the Win Ratio Methodology. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[11] Deepak L. Bhatt,et al. Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. , 2020, Hypertension.
[12] Baofeng Yang,et al. Nonpharmacologic Interventions for Reducing Blood Pressure in Adults With Prehypertension to Established Hypertension , 2020, Journal of the American Heart Association.
[13] Byron C. Jaeger,et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. , 2020, JAMA.
[14] R. Schmieder,et al. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension , 2020, Journal of hypertension.
[15] E. Edelman,et al. Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. , 2020, European heart journal.
[16] R. Whitbourn,et al. Renal Denervation in High-Risk Patients With Hypertension. , 2020, Journal of the American College of Cardiology.
[17] G. Mancia,et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation , 2020 .
[18] Dorairaj Prabhakaran,et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. , 2020, Hypertension.
[19] M. Böhm,et al. Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis. , 2020, Journal of hypertension.
[20] Manesh R. Patel,et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial , 2020, The Lancet.
[21] G. Chatellier,et al. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies , 2020, European heart journal.
[22] C. Lücke,et al. Changes in Stroke Volume After Renal Denervation , 2020, Hypertension.
[23] K. Kario,et al. Seasonal variation in blood pressure: Evidence, consensus and recommendations for clinical practice. Consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. , 2020, Journal of hypertension.
[24] A. Bhowmik,et al. Trial Randomised controlled trial , 2020 .
[25] G. Molenberghs,et al. Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints , 2019, Statistics in medicine.
[26] Yaiza Beatriz Molero-Díez,et al. Fourth universal definition of myocardial infarction , 2019, Colombian Journal of Anesthesiology.
[27] K. Kario,et al. Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy , 2019, Hypertension.
[28] H. Thiele,et al. Renal Denervation in Isolated Systolic Hypertension Using Different Catheter Techniques and Technologies. , 2019, Hypertension.
[29] A. Kirtane,et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. , 2019, Circulation.
[30] Jonathan H Seltzer,et al. Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document. , 2019, JACC. Cardiovascular interventions.
[31] Jackson T. Wright,et al. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. , 2019, Hypertension.
[32] S. Pocock,et al. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial , 2019, European heart journal.
[33] M. James,et al. Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular and Other Major Clinical Outcomes: A Systematic Review and Meta-analysis. , 2019, The Canadian journal of cardiology.
[34] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.
[35] Kristian Thygesen,et al. Fourth Universal Definition of Myocardial Infarction (2018). , 2018, Journal of the American College of Cardiology.
[36] G. Lip,et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.
[37] J. Spertus,et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document , 2018, European heart journal.
[38] S. Pocock,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.
[39] Neil Chapman,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.
[40] Jeffrey N. Browndyke,et al. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative , 2018, European heart journal.
[41] C. Tsioufis,et al. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis , 2018, Journal of hypertension.
[42] J. Staessen,et al. Blood pressure response to renal denervation is correlated with baseline blood pressure variability: a patient-level meta-analysis. , 2018, Journal of hypertension.
[43] C. Ott,et al. Renal denervation improves 24‐hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance , 2018, Journal of clinical hypertension.
[44] Daniel W. Jones,et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline , 2018, Circulation.
[45] Akshay S. Desai,et al. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.
[46] G. Stone,et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study , 2017, The Lancet.
[47] Neil Chapman,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.
[48] N. Samani,et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence , 2017, Hypertension.
[49] J. Gladman,et al. Withdrawal of antihypertensive medication: a systematic review , 2017, Journal of hypertension.
[50] G. Mancia,et al. Improvement in health‐related quality of life after renal sympathetic denervation in real‐world hypertensive patients: 12‐month outcomes in the Global SYMPLICITY Registry , 2017, Journal of clinical hypertension.
[51] Jeffrey N. Browndyke,et al. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. , 2017, Journal of the American College of Cardiology.
[52] Deepak L. Bhatt,et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry , 2016, European heart journal.
[53] Deepak L. Bhatt,et al. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. , 2016, Journal of the American College of Cardiology.
[54] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[55] R. Townsend,et al. Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. , 2016, Journal of the American Society of Hypertension : JASH.
[56] C. Escobar Cervantes,et al. [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.
[57] M. Uder,et al. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension , 2015, Journal of hypertension.
[58] P. Gosse,et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.
[59] E. Vink,et al. Denervation of the Renal Arteries in Metabolic Syndrome: The DREAMS-Study , 2015, Hypertension.
[60] G. Mancia,et al. Clinical value of ambulatory blood pressure: evidence and limits. , 2015, Circulation research.
[61] G. Grassi,et al. Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy: an EnligHTN I substudy , 2015, Journal of hypertension.
[62] I. Meredith,et al. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[63] H. Krum,et al. Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials: Implications for Trials of Renal Denervation , 2015, Hypertension.
[64] Deepak L. Bhatt,et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.
[65] Deepak L. Bhatt,et al. Non-adherence to cardiovascular medications. , 2014, European heart journal.
[66] B. Egan,et al. Hypertension in the United States, 1999 to 2012: Progress Toward Healthy People 2020 Goals , 2014, Circulation.
[67] R. Brook,et al. A review of blood pressure measurement protocols among hypertension trials: implications for "evidence-based" clinical practice. , 2014, Journal of the American Society of Hypertension : JASH.
[68] E. Wellnhofer,et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. , 2014, European heart journal.
[69] Geoffrey A Head,et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. , 2014, Journal of hypertension.
[70] Deepak L. Bhatt,et al. Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.
[71] Hassan Khan,et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.
[72] H. Krum,et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. , 2013, International journal of cardiology.
[73] M. Böhm,et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. , 2013, International journal of cardiology.
[74] C. Tsioufis,et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial , 2013, European heart journal.
[75] Gianfranco Parati,et al. Assessment and management of blood-pressure variability , 2013, Nature Reviews Cardiology.
[76] A. Hughes,et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. , 2013, International journal of cardiology.
[77] Deborah Marshall,et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[78] Dominik Linz,et al. Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2012, Hypertension.
[79] M. Böhm,et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. , 2012, Journal of the American College of Cardiology.
[80] M. Mack,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, European heart journal.
[81] M. Krucoff,et al. The academic research consortium governance charter. , 2011, JACC. Cardiovascular interventions.
[82] R. Agarwal,et al. Home Blood Pressure Monitoring: How Good a Predictor of Long-Term Risk? , 2011, Current hypertension reports.
[83] H. Krum,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.
[84] Jens Jordan,et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. , 2010, Journal of the American College of Cardiology.
[85] I. Hajjar,et al. A novel measurement index for antihypertensive medication burden and its use. , 2009, Hypertension.
[86] Krzysztof Bartus,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.
[87] J. Ménard,et al. Teletransmission of home blood pressure monitoring: making it easier. , 2008, Journal of hypertension.
[88] G. Mancia,et al. Neurogenic Abnormalities in Masked Hypertension , 2007, Hypertension.
[89] Alice Stanton,et al. Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality: The Dublin Outcome Study , 2005, Hypertension.
[90] Roberto Sega,et al. Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study , 2005, Circulation.
[91] K. Reynolds,et al. Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.
[92] M. Nieminen,et al. Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.
[93] Paul A. Smith,et al. Sympathetic neural mechanisms in white-coat hypertension. , 2002, Journal of the American College of Cardiology.
[94] Gianfranco Parati,et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. , 1999 .
[95] G Parati,et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. , 1999, JAMA.
[96] F. Abboud,et al. Sympathetic neural mechanisms in obstructive sleep apnea. , 1995, The Journal of clinical investigation.